RARE Ultragenyx Pharmaceutical Inc.
Healthcare$23.14-1.07%ClosedMarket Cap: $2.28B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
-9.97
P/S
3.44
EV/EBITDA
-6.47
DCF Value
$-409.56
FCF Yield
-21.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.6%
Operating Margin
-83.9%
Net Margin
-91.0%
ROE
1566.9%
ROA
-47.0%
ROIC
-53.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $136.0M | 77.9% | $-169.0M | $-185.0M | $— | — |
| Q4 null | $207.0M | 86.0% | $-114.0M | $-129.0M | $— | — |
| FY null | $673.0M | 83.8% | $-535.0M | $-575.0M | $— | — |
| Q3 null | $159.9M | 82.5% | $-170.9M | $-180.4M | $— | — |
| Q2 null | $166.5M | 86.2% | $-107.9M | $-115.0M | $— | — |
| Q1 null | $139.3M | 79.4% | $-142.9M | $-151.1M | $— | — |
| Q4 null | $164.9M | 89.8% | $-122.3M | $-133.4M | $— | — |
| FY null | $560.2M | 86.3% | $-536.0M | $-569.2M | $— | — |
| Q3 null | $139.5M | 84.9% | $-132.0M | $-133.5M | $— | — |
| Q2 null | $147.0M | 85.5% | $-116.4M | $-131.6M | $— | — |
| Q1 null | $108.8M | 83.9% | $-165.3M | $-170.7M | $— | — |
| Q4 2023 | $127.4M | 90.5% | $-122.0M | $-123.2M | $-1.52 | — |